Antidrug antibodies against TNF-blocking agents: Correlations between disease activity, hypersensitivity reactions, and different classes of immunoglobulins

Biologics: Targets and Therapy

Volumn 9, Issue , 2015, Pages 7-12

  Benucci, Maurizio ^a   Gobbi, Francesca Li ^a   Meacci, Francesca ^b   Manfredi, Mariangela ^b   Infantino, Maria ^b   Severino, Maurizio ^c   Testi, Sergio ^c   Sarzi Puttini, Piercarlo ^d   Ricci, Cristian ^e   Atzeni, Fabiola ^f  

^a Rheumatology Unit   (Italy)

^b Immunology and Allergology Laboratory Unit   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF REGENSBURG   (Germany)

^f IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Antidrug antibodies; IgG4 antibodies; TNF blocking agents

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; INFLIXIMAB; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DAS28; DISEASE ACTIVITY; DISEASE DURATION; DRUG SAFETY; FEMALE; HUMAN; HYPERSENSITIVITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; REMISSION; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 84922990200     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S69606     Document Type: Article

References (21)

1. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165–178.
2. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol. 2003;98:1315–1324.
3. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:40–46.
4. Pichler WJ, Campi P. Adverse side effects to biological agents. In: Pichler WJ, editor. Drug Hypersensitivity. Basel: Karger; 2007: 160–174.
5. Parish WE. Short term anaphylactic IgG antibodies in human sera. Lancet. 1970;19;2(7673):591–592.
6. van Schouwenburg PA, Krieckaert CL, Nurmohamed M, et al. IgG4 production against adalimumab during long term treatment of RA patients. J Clin Immunol. 2012;32:1000–1006.
7. Aalberse RC, van der Gaag R, van Leeuwen LJ. Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol. 1983;130:722–726.
8. Tao MH, Canfield SM, Morrison SL. The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain. J Exp Med. 1991;173: 1025–1028.
9. Nirula A, Glaser SM, Kalled SL, Taylor FR. What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr Opin Rheumatol. 2011;23:119–124.
10. Van Der Zee JS, Van Swieten P, Aalberse RC. Serologic aspects of IgG4 antibodies. II. IgG4 antibodies form small, nonprecipitating immune complexes due to functional monovalency. J Immunol. 1986;137: 3566–3571.
11. van der Neut KM, Schuurman J, Losen M, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317:1554–1557.
12. van der Giessen M, Homan WL, van Kernbeek G, Aalberse RC, Dieges PH. Subclass typing of IgG antibodies formed by grass pollen-allergic patients during immunotherapy. Int Arch Allergy Appl Immunol. 1976;50:625–640.
13. Gehlhar K, Schlaak M, Becker W, Bufe A. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy. 1999;29: 497–506.
14. Nouri-Aria KT, Wachholz PA, Francis JN, et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocks IgG activity. J Immunol. 2004;172:3252–3259.
15. Deisenhammer F, Reindl M, Berger T. Immunoglobulin subclasses in patients with neutralizing and non-neutralizing antibodies against IFN-β1b. J Interferon Cytokine Res. 2001;21:167–171.
16. Svenson M, Geborek P, Saxne T, Bendtzen K. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infiximab and anti-infiximab antibodies. Rheumatology (Oxford). 2007;46:1828–1834.
17. Wouters D, Stapel S, Vis M, et al. Human antichimeric antibodies to infliximab and infusion-related allergic reactions in patients with rheumatoid arthritis. Allergy Clin Immunol Int. 2007;2:198–200.
18. Aalberse RC, Stapel SO, Schuurman J, Rispens T. Immunoglobulin G4: an odd antibody. Clin Exp Allergy. 2009;39:469–477.
19. van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak P P. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69:624–625.
20. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921–926.
21. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–1468.